1.79
price up icon0.56%   0.01
after-market アフターアワーズ: 1.77 -0.02 -1.12%
loading
前日終値:
$1.78
開ける:
$1.73
24時間の取引高:
40,216
Relative Volume:
0.45
時価総額:
$84.36M
収益:
$18.11M
当期純損益:
$-18.95M
株価収益率:
-4.0914
EPS:
-0.4375
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.98%
1か月 パフォーマンス:
-9.60%
6か月 パフォーマンス:
+16.99%
1年 パフォーマンス:
-40.33%
1日の値動き範囲:
Value
$1.70
$1.80
1週間の範囲:
Value
$1.70
$1.93
52週間の値動き範囲:
Value
$1.325
$3.16

Adagene Inc Adr Stock (ADAG) Company Profile

Name
名前
Adagene Inc Adr
Name
セクター
Healthcare (1136)
Name
電話
-
Name
住所
-
Name
職員
138
Name
Twitter
Name
次回の収益日
2024-03-28
Name
最新のSEC提出書
Name
ADAG's Discussions on Twitter

ADAG を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ADAG
Adagene Inc Adr
1.79 83.89M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.00 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.25 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.07 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
826.28 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
186.23 40.44B 447.02M -1.18B -868.57M -6.1812

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-06 開始されました Leerink Partners Outperform
2025-01-31 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-06-25 開始されました China Renaissance Buy
2021-03-08 開始されました Goldman Buy
2021-03-08 開始されました Jefferies Buy
2021-03-08 開始されました Morgan Stanley Overweight
すべてを表示

Adagene Inc Adr (ADAG) 最新ニュース

pulisher
Nov 02, 2025

What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptMarket Rally & Entry Point Confirmation Alerts - newser.com

Nov 02, 2025
pulisher
Oct 31, 2025

Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com

Oct 31, 2025
pulisher
Oct 31, 2025

Adagene Inc. Initiates Phase 2 Clinical Trial of Muzastotug in Combination with KEYTRUDA for Colorectal Cancer - Quiver Quantitative

Oct 31, 2025
pulisher
Oct 31, 2025

Adagene (NASDAQ: ADAG) opens randomized Phase 2 muzastotug + Keytruda trial in MSS CRC - Stock Titan

Oct 31, 2025
pulisher
Oct 25, 2025

Adagene (NASDAQ:ADAG) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 25, 2025
pulisher
Oct 22, 2025

Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Grows By 66.4% - MarketBeat

Oct 22, 2025
pulisher
Oct 20, 2025

CEO Change: Why analysts raise outlook for Adagene Inc. (Common Stock) (978) stockForecast Cut & High Accuracy Swing Entry Alerts - Trung tâm Dự báo KTTV quốc gia

Oct 20, 2025
pulisher
Oct 18, 2025

Will Adagene Inc. Depositary Receipt stock recover faster than marketDip Buying & Safe Entry Trade Signal Reports - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 09, 2025

Chart based analysis of Adagene Inc. Depositary Receipt trendsBreakout Watch & Advanced Swing Trade Entry Plans - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Weiss Ratings Reaffirms Sell (D-) Rating for Adagene (NASDAQ:ADAG) - MarketBeat

Oct 08, 2025
pulisher
Oct 04, 2025

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Up 320.2% in September - Defense World

Oct 04, 2025
pulisher
Oct 02, 2025

Adagene Inc. (ADAG) stock price, news, quote and history - Yahoo! Finance UK

Oct 02, 2025
pulisher
Oct 02, 2025

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Increase in Short Interest - MarketBeat

Oct 02, 2025
pulisher
Sep 30, 2025

All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

How sentiment analysis helps forecast Adagene Inc. Depositary ReceiptMarket Growth Review & AI Driven Price Forecasts - newser.com

Sep 30, 2025
pulisher
Sep 25, 2025

Are Medical Stocks Lagging Adagene (ADAG) This Year? - sharewise.com

Sep 25, 2025
pulisher
Sep 19, 2025

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat

Sep 19, 2025
pulisher
Sep 18, 2025

Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India

Sep 18, 2025
pulisher
Sep 16, 2025

Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative

Sep 16, 2025
pulisher
Sep 16, 2025

Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire

Sep 16, 2025
pulisher
Sep 16, 2025

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener

Sep 16, 2025
pulisher
Sep 16, 2025

Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan

Sep 16, 2025
pulisher
Sep 15, 2025

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World

Sep 15, 2025
pulisher
Sep 14, 2025

Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com

Sep 14, 2025
pulisher
Sep 10, 2025

Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser

Sep 10, 2025
pulisher
Sep 10, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Sep 10, 2025
pulisher
Sep 10, 2025

Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser

Sep 10, 2025
pulisher
Sep 08, 2025

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Sep 08, 2025
pulisher
Sep 07, 2025

Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat

Sep 07, 2025
pulisher
Sep 05, 2025

Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times

Sep 05, 2025
pulisher
Sep 05, 2025

Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative

Sep 05, 2025
pulisher
Sep 05, 2025

30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan

Sep 05, 2025
pulisher
Sep 03, 2025

Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative

Sep 03, 2025
pulisher
Sep 03, 2025

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - The Manila Times

Sep 03, 2025
pulisher
Sep 03, 2025

Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan

Sep 03, 2025
pulisher
Sep 03, 2025

Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک

Sep 03, 2025
pulisher
Sep 01, 2025

Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک

Sep 01, 2025
pulisher
Aug 29, 2025

What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser

Aug 29, 2025
pulisher
Aug 26, 2025

Adagene to Participate in Two Investor Conferences in September - The Manila Times

Aug 26, 2025
pulisher
Aug 26, 2025

Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan

Aug 26, 2025
pulisher
Aug 23, 2025

Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser

Aug 23, 2025
pulisher
Aug 21, 2025

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Aug 21, 2025
pulisher
Aug 19, 2025

What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser

Aug 19, 2025
pulisher
Aug 17, 2025

HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com

Aug 15, 2025
pulisher
Aug 14, 2025

Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest

Aug 14, 2025

Adagene Inc Adr (ADAG) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
大文字化:     |  ボリューム (24 時間):